CA2925402A1 - Methods for treating chronic obstructive pulmonary disease using benralizumab - Google Patents
Methods for treating chronic obstructive pulmonary disease using benralizumab Download PDFInfo
- Publication number
- CA2925402A1 CA2925402A1 CA2925402A CA2925402A CA2925402A1 CA 2925402 A1 CA2925402 A1 CA 2925402A1 CA 2925402 A CA2925402 A CA 2925402A CA 2925402 A CA2925402 A CA 2925402A CA 2925402 A1 CA2925402 A1 CA 2925402A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- copd
- benralizumab
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229950000321 benralizumab Drugs 0.000 title claims abstract description 239
- 238000000034 method Methods 0.000 title claims abstract description 197
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims description 247
- 239000012634 fragment Substances 0.000 claims abstract description 172
- 239000000427 antigen Substances 0.000 claims abstract description 171
- 102000036639 antigens Human genes 0.000 claims abstract description 171
- 108091007433 antigens Proteins 0.000 claims abstract description 171
- 210000003979 eosinophil Anatomy 0.000 claims description 147
- 229940124630 bronchodilator Drugs 0.000 claims description 132
- 230000005713 exacerbation Effects 0.000 claims description 104
- 208000024891 symptom Diseases 0.000 claims description 66
- 229940125389 long-acting beta agonist Drugs 0.000 claims description 39
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 36
- 230000000241 respiratory effect Effects 0.000 claims description 31
- 101100384805 Homo sapiens ARCN1 gene Proteins 0.000 claims description 30
- 239000003246 corticosteroid Substances 0.000 claims description 30
- 229960001334 corticosteroids Drugs 0.000 claims description 27
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 27
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims description 23
- 230000007423 decrease Effects 0.000 claims description 23
- 239000000556 agonist Substances 0.000 claims description 19
- 229940110309 tiotropium Drugs 0.000 claims description 11
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 abstract description 8
- 230000000414 obstructive effect Effects 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 2
- 230000008859 change Effects 0.000 description 88
- 239000000902 placebo Substances 0.000 description 40
- 229940068196 placebo Drugs 0.000 description 40
- 238000011282 treatment Methods 0.000 description 26
- 208000000059 Dyspnea Diseases 0.000 description 24
- 206010013975 Dyspnoeas Diseases 0.000 description 24
- 206010036790 Productive cough Diseases 0.000 description 20
- 210000003802 sputum Anatomy 0.000 description 20
- 208000024794 sputum Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000013125 spirometry Methods 0.000 description 18
- 230000009885 systemic effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000003862 health status Effects 0.000 description 10
- 229960002052 salbutamol Drugs 0.000 description 10
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 230000009798 acute exacerbation Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229940127558 rescue medication Drugs 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000004199 lung function Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 206010047924 Wheezing Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 102000057955 Eosinophil Cationic Human genes 0.000 description 4
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 4
- 206010027590 Middle insomnia Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 3
- 206010014950 Eosinophilia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010061926 Purulence Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229940124624 oral corticosteroid Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940035073 symbicort Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 description 2
- 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- -1 i.e. Chemical compound 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000011545 laboratory measurement Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 238000011418 maintenance treatment Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 229940046810 spiriva Drugs 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000025678 Ciliary Motility disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001218102 Phytophthora alphaendornavirus 1 Species 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- AKYNJTFOHFQPEM-JRLZQBLDSA-N foradil-combi Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O AKYNJTFOHFQPEM-JRLZQBLDSA-N 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 102000043881 human IL5RA Human genes 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229940125387 short-acting bronchodilator Drugs 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891175P | 2013-10-15 | 2013-10-15 | |
| US61/891,175 | 2013-10-15 | ||
| US201461970126P | 2014-03-25 | 2014-03-25 | |
| US61/970,126 | 2014-03-25 | ||
| PCT/US2014/060432 WO2015057668A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2925402A1 true CA2925402A1 (en) | 2015-04-23 |
Family
ID=52809872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2925402A Abandoned CA2925402A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Country Status (12)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105164157B (zh) | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| AU2016272399B2 (en) | 2015-06-01 | 2021-09-09 | Kyowa Kirin Co., Ltd. | Therapeutic agent and therapeutic method for pulmonary hypertension |
| CN109544378B (zh) * | 2018-10-27 | 2024-06-25 | 平安医疗健康管理股份有限公司 | 一种肺源性心脏病资质认证方法、设备及服务器 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| JP7696900B2 (ja) * | 2019-12-06 | 2025-06-23 | サノフィ・バイオテクノロジー | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| WO2023034993A1 (en) * | 2021-09-03 | 2023-03-09 | Gleich Gerald J | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| PT1176195E (pt) * | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| AU2001232304A1 (en) * | 2000-02-15 | 2001-08-27 | Kyowa Hakko Kogyo Co. Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| US20100291073A1 (en) * | 2007-05-14 | 2010-11-18 | Medimmune, Llc | Methods of reducing eosinophil levels |
| CN101249093A (zh) * | 2008-03-19 | 2008-08-27 | 李虎山 | 一种治疗慢性阻塞性肺部疾病的组合物 |
| RU2013122123A (ru) * | 2010-10-15 | 2014-11-20 | Медиммьюн Лимитед | Терапевтические средства для улучшения легочной функции |
| EP2652498B1 (en) * | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
| US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| CN104039352A (zh) * | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| SG11201600484TA (en) * | 2013-08-12 | 2016-02-26 | Medimmune Llc | Methods for improving asthma symptoms using benralizumab |
| HUE042607T2 (hu) * | 2013-08-12 | 2019-07-29 | Astrazeneca Ab | Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával |
| CN111588849A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 |
-
2014
- 2014-10-14 CN CN201480056549.0A patent/CN105636607A/zh active Pending
- 2014-10-14 AU AU2014334563A patent/AU2014334563A1/en not_active Abandoned
- 2014-10-14 US US14/513,866 patent/US20150104447A1/en not_active Abandoned
- 2014-10-14 EP EP14853201.3A patent/EP3057609A4/en not_active Withdrawn
- 2014-10-14 MX MX2016004329A patent/MX2016004329A/es unknown
- 2014-10-14 CA CA2925402A patent/CA2925402A1/en not_active Abandoned
- 2014-10-14 CN CN202110508239.XA patent/CN113230399A/zh active Pending
- 2014-10-14 RU RU2016118425A patent/RU2706729C2/ru active
- 2014-10-14 SG SG10201807318RA patent/SG10201807318RA/en unknown
- 2014-10-14 EP EP18189626.7A patent/EP3485902A1/en not_active Withdrawn
- 2014-10-14 SG SG11201601807XA patent/SG11201601807XA/en unknown
- 2014-10-14 KR KR1020167009675A patent/KR20160061352A/ko not_active Ceased
- 2014-10-14 BR BR112016008082A patent/BR112016008082A2/pt not_active Application Discontinuation
- 2014-10-14 WO PCT/US2014/060432 patent/WO2015057668A1/en not_active Ceased
- 2014-10-14 JP JP2016523209A patent/JP2016534996A/ja active Pending
-
2016
- 2016-04-04 MX MX2019013468A patent/MX2019013468A/es unknown
- 2016-05-31 US US15/168,711 patent/US20170107291A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,526 patent/US20180291108A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,212 patent/US20200123262A1/en not_active Abandoned
- 2019-07-18 JP JP2019132432A patent/JP6870037B2/ja active Active
-
2020
- 2020-04-02 AU AU2020202333A patent/AU2020202333A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068065A patent/JP2021107421A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019013468A (es) | 2020-02-12 |
| SG11201601807XA (en) | 2016-04-28 |
| BR112016008082A2 (pt) | 2017-10-17 |
| WO2015057668A1 (en) | 2015-04-23 |
| CN113230399A (zh) | 2021-08-10 |
| RU2706729C2 (ru) | 2019-11-20 |
| CN105636607A (zh) | 2016-06-01 |
| KR20160061352A (ko) | 2016-05-31 |
| RU2016118425A3 (cg-RX-API-DMAC7.html) | 2018-07-19 |
| JP2016534996A (ja) | 2016-11-10 |
| US20200123262A1 (en) | 2020-04-23 |
| SG10201807318RA (en) | 2018-09-27 |
| JP2021107421A (ja) | 2021-07-29 |
| US20180291108A1 (en) | 2018-10-11 |
| MX2016004329A (es) | 2016-11-10 |
| JP2019203009A (ja) | 2019-11-28 |
| AU2014334563A1 (en) | 2016-04-07 |
| AU2020202333A1 (en) | 2020-04-23 |
| RU2016118425A (ru) | 2017-11-21 |
| EP3485902A1 (en) | 2019-05-22 |
| US20170107291A1 (en) | 2017-04-20 |
| JP6870037B2 (ja) | 2021-05-12 |
| EP3057609A4 (en) | 2017-03-22 |
| EP3057609A1 (en) | 2016-08-24 |
| US20150104447A1 (en) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200123262A1 (en) | Methods For Treating Chronic Obstructive Pulmonary Disease Using Benralizumab | |
| US20240409626A1 (en) | Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab | |
| HK40008332A (en) | Methods for treating chronic obstructive pulmonary disease using benralizumab | |
| HK1224583A1 (en) | Methods for treating chronic obstructive pulmonary disease using benralizumab | |
| US20230348606A1 (en) | Methods for treating severe asthma in patients with nasal polyposis | |
| US20210095037A1 (en) | Methods for treating late-onset asthma using benralizumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220927 |
|
| FZDE | Discontinued |
Effective date: 20220927 |